Drug Approval | October 14, 2024
Indoco Remedies receives OAI status from USFDA for Goa plant 2 & 3
Indoco is comprehensively working on the remedial action plan
Indoco is comprehensively working on the remedial action plan
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Subscribe To Our Newsletter & Stay Updated
